163 related articles for article (PubMed ID: 35328227)
1. Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.
Bruno R; Poma AM; Alì G; Distefano C; Proietti A; Chella A; Lucchi M; Melfi F; Franco R; Fontanini G
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328227
[TBL] [Abstract][Full Text] [Related]
2. New Immunohistochemical Markers for Pleural Mesothelioma Subtyping.
Di Stefano I; Alì G; Poma AM; Bruno R; Proietti A; Niccoli C; Zirafa CC; Melfi F; Mastromarino MG; Lucchi M; Fontanini G
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761312
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series.
Bruno R; Poma AM; Alì G; Proietti A; Ribechini A; Chella A; Fontanini G
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067238
[TBL] [Abstract][Full Text] [Related]
4. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
5. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
6. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of histological subtyping of malignant pleural mesothelioma.
Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
[TBL] [Abstract][Full Text] [Related]
9. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
10. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
12. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of histologic subtyping of malignant pleural mesothelioma.
Brcic L; Kern I
Transl Lung Cancer Res; 2020 Jun; 9(3):924-933. PubMed ID: 32676358
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
[TBL] [Abstract][Full Text] [Related]
15. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Alchami FS; Attanoos RL; Bamber AR
J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
[TBL] [Abstract][Full Text] [Related]
16. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH; Haberecker M; Tsourti Z; Nackaerts K; de Perrot M; Brcic L; Nadal E; Tsimpoukis S; Gray SG; Ampollini L; Aerts JG; Felley-Bosco E; Kirschner MB; Monkhorst K; Weynand B; Bavaghar-Zaeimi F; Samarzija M; Llatjos R; Finn SP; Silini E; von der Thüsen J; Marti N; Vervita K; Kammler R; Peters S; Stahel RA; Baas P; Opitz I;
Mod Pathol; 2022 Dec; 35(12):1888-1899. PubMed ID: 36115922
[TBL] [Abstract][Full Text] [Related]
17. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
18. The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition.
Felley-Bosco E; Qi W; Jean D; Meiller C; Rehrauer H
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769192
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]